Daiichi Sankyo, Inc. will reorganize its US commercial organization as it begins to transition from a maturing primary care product portfolio to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management, and oncology.

As part of the reorganization, the company will reduce expenses, including a reduction in headcount, from its US commercial operations. The company expects to eliminate 1,000 to 1,200 positions across the US commercial function, through voluntary and involuntary displacements as well as eliminating open positions. The eliminated jobs will come from the US commercial home office, located in Parsippany, New Jersey, as well as field-based sales and other positions throughout the country. This reorganization is not focused on US-based R&D functions, which have staff concentrated in Edison, New Jersey or its packaging plant in Bethlehem, Pennsylvania.

“As we face the loss of exclusivity in the coming year of our largest product, we also look ahead to great opportunities with our emerging portfolio in cardiology, oncology, fibromyalgia, and pain relief,” said Ken Keller, president, US Commercial, Daiichi Sankyo, Inc., in a company statement.”This calls for us to restructure our organization into a smaller, highly targeted and efficient operating model, with a greater emphasis on customer-facing roles.”

Source: Daiichi Sankyo